Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:RHHBY NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRHHBYRoche$50.80-1.6%$51.78$35.07▼$60.85$323.62B0.52.51 million shs369,440 shsSRPTSarepta Therapeutics$20.24-12.1%$19.73$10.41▼$44.14$2.14B0.262.88 million shs2.82 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRHHBYRoche+1.55%+2.64%+3.30%-9.61%+26.86%SRPTSarepta Therapeutics+5.69%+11.42%+1.01%+35.23%-50.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRHHBYRoche$50.80-1.6%$51.78$35.07▼$60.85$323.62B0.52.51 million shs369,440 shsSRPTSarepta Therapeutics$20.24-12.1%$19.73$10.41▼$44.14$2.14B0.262.88 million shs2.82 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRHHBYRoche+1.55%+2.64%+3.30%-9.61%+26.86%SRPTSarepta Therapeutics+5.69%+11.42%+1.01%+35.23%-50.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRHHBYRoche 2.45Hold$51.501.38% UpsideSRPTSarepta Therapeutics 2.11Hold$30.7752.02% UpsideCurrent Analyst Ratings BreakdownLatest SRPT and RHHBY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026RHHBYRoche Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$46.004/22/2026SRPTSarepta Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)4/16/2026SRPTSarepta Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell4/7/2026SRPTSarepta Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$18.00 ➝ $19.004/6/2026RHHBYRoche ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy3/26/2026SRPTSarepta Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$29.00 ➝ $35.003/26/2026SRPTSarepta Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$12.00 ➝ $14.003/26/2026SRPTSarepta Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$9.00 ➝ $13.003/26/2026SRPTSarepta Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderperform3/19/2026SRPTSarepta Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$37.003/12/2026SRPTSarepta Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$26.00 ➝ $31.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRHHBYRoche$76.45B4.23$3.60 per share14.12$7.18 per share7.08SRPTSarepta Therapeutics$2.20B0.97N/AN/A$10.89 per share1.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRHHBYRoche$15.55BN/AN/A14.474.18N/AN/AN/A7/23/2026 (Estimated)SRPTSarepta Therapeutics-$713.41M-$8.44N/A10.020.33-38.34%-50.74%-18.00%N/ALatest SRPT and RHHBY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/25/2026Q4 2025SRPTSarepta Therapeutics-$0.87-$3.58-$2.71-$3.93$390.95 million$442.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthRHHBYRoche$0.971.91%N/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRHHBYRoche0.721.381.12SRPTSarepta Therapeutics0.732.321.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRHHBYRocheN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipRHHBYRocheN/ASRPTSarepta Therapeutics6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRHHBYRoche103,2496.37 billionN/ANot OptionableSRPTSarepta Therapeutics1,372105.57 million98.29 millionOptionableSRPT and RHHBY HeadlinesRecent News About These CompaniesSarepta Therapeutics, Inc. Q1 2026 Earnings Call Summary1 hour ago | app.moby.coASarepta Stock Slumps. Why an Earnings Beat Wasn’t Enough for the S&P 500 Loser.1 hour ago | finance.yahoo.comSarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?1 hour ago | finance.yahoo.comSarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained1 hour ago | zacks.comSarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution Uncertainties4 hours ago | tipranks.comSarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price TargetMay 7 at 6:51 AM | tipranks.comSarepta Therapeutics Q1 Earnings Call HighlightsMay 7 at 2:06 AM | marketbeat.comSarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call TranscriptMay 6 at 12:01 AM | seekingalpha.comSarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate DevelopmentsMay 6 at 8:59 PM | finance.yahoo.comSarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top EstimatesMay 6 at 8:59 PM | finance.yahoo.comSarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to SayMay 6 at 8:59 PM | finance.yahoo.comSarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check.May 6 at 8:59 PM | finance.yahoo.comSarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to SayMay 6 at 7:31 PM | zacks.comSarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top EstimatesMay 6 at 6:25 PM | zacks.comSarepta Therapeutics (NASDAQ:SRPT) Releases Quarterly Earnings ResultsMay 6 at 4:26 PM | marketbeat.comSarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate DevelopmentsMay 6 at 4:05 PM | businesswire.comSarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings GrowthApril 29, 2026 | finance.yahoo.comSarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings GrowthApril 29, 2026 | zacks.comM&T Bank Corp Acquires Shares of 83,348 Sarepta Therapeutics, Inc. $SRPTApril 29, 2026 | marketbeat.comSarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on WednesdayApril 29, 2026 | marketbeat.comA Look At Sarepta Therapeutics (SRPT) Valuation After Recent Share Price VolatilityApril 22, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSRPT and RHHBY Company DescriptionsRoche OTCMKTS:RHHBY$50.80 -0.83 (-1.61%) As of 12:48 PM EasternRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.Sarepta Therapeutics NASDAQ:SRPT$20.24 -2.79 (-12.11%) As of 01:06 PM Eastern This is a fair market value price provided by Massive. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
